ClinicalTrials.gg
Active, not recruitingNCT05432310Updated Aug 20, 2026

Gene Therapy for Adenosine Deaminase Severe Combined Immune Deficiency Using Peripheral Blood and EFS ADA Vector

A Phase 1/2 interventional study of A cryopreserved formulation of autologous mPB CD34+ hematopoietic stem and progenitor cells transduced ex vivo with the EFS-ADA lentiviral vector encoding the human ADA enzyme in Adenosine Deaminase Severe Combined Immune Deficiency, sponsored by University of California, Los Angeles. Active, not recruiting at 1 site in United States. Open to participants aged 1 Month and older. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by University of California, Los Angeles · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
1 Month and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Severe combined immunodeficiency due to adenosine deaminase deficiency with a site in United States — 2 open to participants now, 4 under way, none of them phase 3. Severe combined immunodeficiency due to adenosine deaminase deficiency · United States.

Started
2023
the only one that year
Phase 1/2
3 of 16
none open now
Registered
16th of 16
by date
Lead sponsor
5 of 16
University of California, Los Angeles

Among the 16 studies in Severe combined immunodeficiency due to adenosine deaminase deficiency with a site in United States, this one is the only one that started in 2023, is one of 3 in phase 1/2, and was the 16th registered.

Severe combined immunodeficiency due to adenosine deaminase deficiency

29 studies on the registry are indexed under Severe combined immunodeficiency due to adenosine deaminase deficiency; 4 are open to participants now.

Browse Severe combined immunodeficiency due to adenosine deaminase deficiency studies →

Open to participants now

2 of the 16 studies in Severe combined immunodeficiency due to adenosine deaminase deficiency with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Severe combined immunodeficiency due to adenosine deaminase deficiency with a site in United States, or all of them as a file.
02

Study summary

The aim of this study is to assess the safety and efficacy of autologous transplantation of hematopoietic stem cells (CD34+ cells) from mobilized peripheral blood (mPB) of ADA-deficient SCID infants and children following human ADA gene transfer by the EFS-ADA lentiviral vector. The level of gene transfer in blood cells and immune function will be measured as endpoints.

Read the detailed description

The study is open to twenty (20) infants and children diagnosed with ADA-deficient SCID who did not have a medically eligible, human leukocyte antigen (HLA)-identical sibling donor for bone marrow transplantation. The EFS-ADA lentiviral vector with the human ADA complementary DNA (cDNA) will be used to transduce autologous CD34+ cells from Granulocyte Colony Stimulating Factor (G-CSF)/Plerixafor mobilized Peripheral Blood (mPB) of these subjects. The subjects will receive pharmacokinetically-adjusted busulfan reduced intensity conditioning prior to re-infusion of their gene-modified cells. Overall survival at two years is the primary endpoint. During the follow-up phase, the investigators aim to determine whether the cells could engraft and produce mature cells that contain and express the corrected ADA gene in the absence of pegylated adenosine deaminase (PEG-ADA) enzyme replacement therapy (ERT), which will be withheld starting on Day +30 following transplant. Efficacy studies to evaluate the level of immune reconstitution, will be performed in the two years of the study. Patients will be asked to enroll into a long-term follow-up study to reach a total of 15 years follow-up after gene therapy.

03

Conditions studied

  • Adenosine Deaminase Severe Combined Immune Deficiency

Keywords

  • Gene Therapy
  • Hematopoietic Stem Cell
  • Lentiviral Vector
  • Reduced Intensity Conditioning with Busulfan
04

Who can participate

Ages eligible
1 Month and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All subjects must fulfill the following criteria to be included in the study:

  1. Provision of written prior to any study related procedures. In this study consent must be provided by the parents/legal guardians and, where applicable according to local laws, a signed assent from the child,
  2. Subjects ≥30 days of age,
  3. With a diagnosis of ADA-SCID based on:

    Evidence of ADA deficiency, defined as:

    i. Decreased ADA enzymatic activity in erythrocytes, leukocytes, skin fibroblasts, or in cultured fetal cells to levels consistent with ADA-SCID as determined by the reference laboratory, or ii. Identified mutations in ADA alleles consistent with a severe reduction in ADA activity,

    Evidence of ADA-SCID based on either:

    i. Family history of a first order relative with ADA deficiency and clinical and laboratory evidence of severe immunologic deficiency, or ii. Evidence of severe immunologic deficiency in subjects prior to the institution of immune restorative therapy, based on

    1. Lymphopenia (absolute lymphocyte count (ALC) \<400 cells/mL) OR absence or low number of T cells (absolute CD3+ count \< 300 cells/mL), or
    2. Severely decreased T lymphocyte blastogenic responses to phytohemagglutinin (either \<10% of lower limit of normal controls for the diagnostic laboratory, or \<10% of the response of the normal control of the day, or stimulation index \<10), or
    3. Identification of SCID by neonatal screening revealing low T Cell Receptor Excision Circles (TREC) levels.
  4. Ineligible for matched family allogeneic bone marrow (BM) transplantation, defined as the absence of a medically eligible HLA-identical sibling or family donor, with normal immune function, who could serve as an allogeneic bone marrow donor.
  5. Females of child-bearing age will be required to provide a negative pregnancy test 30 days prior to Visit 2.
  6. Subjects and their parents/legal guardians must be willing and able to comply with study restrictions and to remain at the clinic for the required duration during the study period and willing to return to the clinic for the follow up evaluation as specified in the protocol.

Exclusion criteria

Exclusion Criteria:

Subjects will not be eligible for the study if any of the following criteria is fulfilled:

  1. Ineligible for HSCT as per clinical site criteria
  2. Other conditions which in the opinion of the Principal Investigator and/or Co Investigators, contraindicate the mobilization of peripheral blood or the leukapheresis process, the administration of busulfan and the infusion of transduced cells, or which indicate an inability of the subject or subject's parent/legal guardian to comply with the protocol
  3. Hematologic abnormality, defined as:

    • Anemia ( \<8.0 g/dl).
    • Neutropenia (ANC \<500/mm3). Note: ANC \<500 with absence of myelodysplastic syndrome on bone marrow aspirate and and normal marrow cytogenetics are acceptable for eligibility.
    • Thrombocytopenia ( count \<50,000/mm3, at any age).
    • or international normalized ratio (INR) and partial thromboplastin time (PTT) >2 x (ULN) (subjects with a correctable deficiency controlled on medication will not be excluded).
    • Cytogenetic abnormalities on peripheral blood or bone marrow or amniotic fluid (if available).
    • Prior allogeneic HSCT with cytoreductive conditioning.
  4. Pulmonary abnormality, defined as:

    • Resting O2 saturation by pulse oximetry \<90% on room air.
    • Chest X-ray indicating active or progressive pulmonary disease. Note: Chest X ray indicating residual signs of treated pneumonitis is acceptable for eligibility.
  5. Cardiac abnormality, defined as:

    • Abnormal indicating cardiac pathology.
    • Uncorrected congenital cardiac malformation with clinical symptoms.
    • Active cardiac disease, including clinical evidence of congestive heart failure, cyanosis, hypotension.
    • Poor cardiac function as evidenced by \<40% on echocardiogram.
  6. Neurologic abnormality, defined as:

    • Significant neurologic abnormality revealed by examination.
    • Uncontrolled seizure disorder.
  7. Renal abnormality, defined as:

    • Renal insufficiency: serum creatinine ≥1.2 mg/dl (106 µmol/L), or ≥3+ proteinuria.
    • Abnormal serum sodium, potassium, calcium, magnesium or phosphate levels at >2 x ULN.
  8. Hepatic/gastrointestinal abnormality, defined as:

    • Serum transaminases >5 x ULN.
    • Serum >2 x ULN.
    • Serum glucose >1.5 x ULN.
  9. Oncologic disease, defined as:

    • Evidence of active malignant disease other than dermatofibrosarcoma protuberans (DFSP).
    • Evidence of DFSP expected to require anti-neoplastic therapy within the 5 years following the infusion of genetically corrected cells (if anti-neoplastic therapy has been completed, a subject with a history of DFSP can be included).
    • Evidence of DFSP expected to be life limiting within the 5 years following the infusion of genetically corrected cells.
  10. Known sensitivity to Busulfan.
  11. Confirmation of an infectious disease by deoxyribonucleic acid (DNA) polymerase chain reaction (PCR) positive at time of assessment for the following:

    • -1,
    • ,
    • Parvovirus B19.
  12. The subject is pregnant or has a major congenital anomaly.
  13. Is likely to require treatment during the study with drugs that are not permitted by the study protocol.
  14. The subject has previously received another form of gene therapy.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Autologous mobilized peripheral blood (mPB) transduced with EFS ADA lentiviral vector

    Evaluate safety and efficacy of this autologous gene therapy

    Combination Product: A cryopreserved formulation of autologous mPB CD34+ hematopoietic stem and progenitor cells transduced ex vivo with the EFS-ADA lentiviral vector encoding the human ADA enzyme

Interventions

  • Combination productA cryopreserved formulation of autologous mPB CD34+ hematopoietic stem and progenitor cells transduced ex vivo with the EFS-ADA lentiviral vector encoding the human ADA enzyme

    Autologous transplantation of EFS-ADA lentiviral vector transduced, mPB CD34+ cells by central venous infusion, following reduced intensity conditioning with busulfan

06

What researchers measure

Primary outcomes

  1. Survival

    The primary study outcome will be to determine survival for all subjects 2 years after gene therapy

    Time frame: 24 months

Secondary outcomes

  1. Evaluate Safety from clinical adverse events.

    Evaluate safety of the treatment by recording clinical adverse events (AE).

    Time frame: 24 months

  2. Evaluate Safety from replication competent lentivirus by quantitative polymerase chain reaction (qPCR) assay.

    Evaluate safety by recording incidents of replication competent lentivirus by qPCR assay..

    Time frame: 24 months

  3. Evaluate Safety from vector-related clonal expansion by non-restrictive Linear Amplification Polymerase Chain Reaction (nrLAM-PCR)

    Evaluate safety by recording incidence of vector-related clonal expansion by nrLAM-PCR

    Time frame: 24 months

  4. Record event free survival at 24 months

    Record Event Free Survival as a definition of "failure" of the therapy. Event-free survival is defined as the proportion of subjects alive with no "event", an "event" being the resumption of PEG-ADA ERT or the need for a rescue allogeneic hematopoietic stem cell transplant (HSCT), or death.

    Time frame: 24 months

  5. Determine incidence of Infection over two years after gene therapy

    Determine the incidence and severity of infections post-gene therapy (subsequent to hematopoietic reconstitution). Over 2 years, record the incidence of hospitalizations or outpatient-based treatments for systemic bacterial, fungal, or viral infections (including, but not limited to Cytomegalovirus (CMV) infections).

    Time frame: 24 months

  6. Neuro-developmental Outcomes by neurodevelopmental testing (subjects 5-7 yeas of age)

    Measure neuro-developmental status post-gene therapy. Perform age-appropriate neuro-developmental assessments testing (5- 7 years of age) at baseline and 2 years post-gene therapy - Wechsler Scale of Intelligence

    Time frame: 24 months

  7. Neuro-developmental Outcomes by neurodevelopmental testing (subjects 1 year -42 month of age)

    Measure neuro-developmental status post-gene therapy. Perform age-appropriate neuro-developmental assessments testing (1 year to 42 months of age) at baseline and 2 years post-gene therapy - : Bayley Scale of Infant Development

    Time frame: 24 months

  8. Neuro-developmental Outcomes by Brain Stem Evoked Response (BAER) testing

    Measure neuro-developmental status post-gene therapy - Perform Brainstem Auditory Evoked Response test at baseline and at 2 years.

    Time frame: 24 months

  9. Cessation of immunoglobulin replacement therapy (IgRT).

    Record time post-gene therapy that immunoglobulin replacement therapy (IgRT) is stopped based on defined criteria.

    Time frame: 24 months

Other outcomes

  1. Exploratory Study Objectives to measure biological correlates of efficacy - Vector Copy Number (VCN) in peripheral blood leukocytes

    The Exploratory Study Objectives are to measure biological correlates of efficacy. 1\. Quantify gene marking by vector copy number (VCN) in peripheral blood leukocytes by droplet digital polymerase chain reaction (ddPCR).

    Time frame: 24 months

  2. Exploratory Study Objectives to measure biological correlates of efficacy (Vector integrant diversity)

    The Exploratory Study Objectives are to measure biological correlates of efficacy. 2\. Quantify clonal diversity of vector integrants by non-restrictive Linear Amplification polymerase chain reaction (nrLAM-PCR). nrLAM-PCR identifies all distinct vector integrants in a cell sample from patients. The presence of \>1,000 unique integration sites in a sample indicates diversity of hematopoietic stem cell of clonal engraftment

    Time frame: 24 months

  3. Exploratory Study Objectives to measure biological correlates of efficacy (expressed ADA enzyme in erythrocytes)

    The Exploratory Study Objectives are to measure biological correlates of efficacy. 3\. Measure ADA enzyme activity in erythrocytes as an indicator of expression of functional ADA enzyme from the vector.

    Time frame: 24 months

  4. Exploratory Study Objectives to measure biological correlates of efficacy Deoxyadenosine nucleotides in erythrocytes)

    The Exploratory Study Objectives are to measure biological correlates of efficacy. 4\. Measure total deoxyadenosine nucleotides in erythrocytes.

    Time frame: 24 months

  5. Exploratory Study Objectives to measure biological correlates of efficacy (Immune reconstitution - quantify T and B cell)

    The Exploratory Study Objectives are to measure biological correlates of efficacy. 5\. Assess immune reconstitution by measuring absolute numbers of T and B cells .

    Time frame: 24 months

  6. Exploratory Study Objectives to measure biological correlates of efficacy (Immune reconstitution - measure serum immunoglobulins)

    The Exploratory Study Objectives are to measure biological correlates of efficacy. 6\. Assess immune reconstitution by measuring serum immunoglobulin levels

    Time frame: 24 months

  7. Exploratory Study Objectives to measure biological correlates of efficacy (Immune reconstitution - response to tetanus vaccine)

    The Exploratory Study Objectives are to measure biological correlates of efficacy. 7\. Assess immune reconstitution by measuring response to tetanus vaccine by measuring serum anti-tetanus antibody titers after tetanus vaccination

    Time frame: 24 months

  8. Exploratory Study Objectives to measure biological correlates of efficacy Parent report Quality of Life

    The Exploratory Study Objectives are to measure biological correlates of efficacy. 8\. Parent-Reported Quality of Life (PedsQL 4.0) at baseline and 2 years.

    Time frame: 24 months

07

Study locations

1 site
08

References and documents

Publications

  • Carbonaro DA, Zhang L, Jin X, Montiel-Equihua C, Geiger S, Carmo M, Cooper A, Fairbanks L, Kaufman ML, Sebire NJ, Hollis RP, Blundell MP, Senadheera S, Fu PY, Sahaghian A, Chan RY, Wang X, Cornetta K, Thrasher AJ, Kohn DB, Gaspar HB. Preclinical demonstration of lentiviral vector-mediated correction of immunological and metabolic abnormalities in models of adenosine deaminase deficiency. Mol Ther. 2014 Mar;22(3):607-622. doi: 10.1038/mt.2013.265. Epub 2013 Nov 20. PubMed 24256635 ↗
  • Kohn DB, Booth C, Shaw KL, Xu-Bayford J, Garabedian E, Trevisan V, Carbonaro-Sarracino DA, Soni K, Terrazas D, Snell K, Ikeda A, Leon-Rico D, Moore TB, Buckland KF, Shah AJ, Gilmour KC, De Oliveira S, Rivat C, Crooks GM, Izotova N, Tse J, Adams S, Shupien S, Ricketts H, Davila A, Uzowuru C, Icreverzi A, Barman P, Campo Fernandez B, Hollis RP, Coronel M, Yu A, Chun KM, Casas CE, Zhang R, Arduini S, Lynn F, Kudari M, Spezzi A, Zahn M, Heimke R, Labik I, Parrott R, Buckley RH, Reeves L, Cornetta K, Sokolic R, Hershfield M, Schmidt M, Candotti F, Malech HL, Thrasher AJ, Gaspar HB. Autologous Ex Vivo Lentiviral Gene Therapy for Adenosine Deaminase Deficiency. N Engl J Med. 2021 May 27;384(21):2002-2013. doi: 10.1056/NEJMoa2027675. Epub 2021 May 11. PubMed 33974366 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2023 (actual). Primary completion is estimated for Nov 2027, 58 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2022
First posted
Jun 27, 2022
StartActual
Jan 4, 2023
Primary completionEst.
Nov 14, 2027
CompletionEst.
Dec 31, 2027
Last update
Aug 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05432310
Responsible party
Satiro N De Oliveira (Assistant Professor of Pediatrics, University of California, Los Angeles) — Principal investigator
First posted
Jun 27, 2022
Start date
Jan 4, 2023
Primary completion
Nov 14, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Aug 20, 2026

Study contacts

Satiro De Oliveira, MD
principal investigator · Assistant Professor

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion